Dana Farber Cancer Institute ( Site 0002) — Boston, Massachusetts

Dana Farber Cancer Institute ( Site 0002) is a clinical research site located in Boston, Massachusetts, United States 02215.

Crixeo Health Trust Score: 62/100 (FAIR). This profile has not yet been claimed by the site owner.

Dana Farber Cancer Institute ( Site 0002) has participated in 5 clinical trials with 2 currently active.

Therapeutic areas: Carcinoma, Non-Small-Cell Lung, Hodgkin Disease, Lymphoma, Non-Hodgkin.

Sponsors: Merck Sharp & Dohme LLC.

Sponsor Feasibility Report

Trust Score: 62/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana Farber Cancer Institute ( Site 0002)?

Dana Farber Cancer Institute ( Site 0002) has a Crixeo Trust Score of 62/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana Farber Cancer Institute ( Site 0002) conducted?

Dana Farber Cancer Institute ( Site 0002) has 5 clinical trials on record, with 2 currently active. Their work covers Carcinoma, Non-Small-Cell Lung, Hodgkin Disease, Lymphoma, Non-Hodgkin.

Is Dana Farber Cancer Institute ( Site 0002) accredited by Crixeo Health?

Dana Farber Cancer Institute ( Site 0002) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana Farber Cancer Institute ( Site 0002)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.